Megakaryocyte growth and development factor (MGDF) administered intraperitoneally (IP) to mice causes a dose-dependent thrombocytosis accompanied by a decrease in mean platelet volume. MGDF increases the number of megakaryocytes in the bone marrow and spleen. MGDF does not affect the circulating number of leukocytes. Carboplatin, a chemotherapeutic agent that causes thrombocytopenia in humans, administered to mice as a single IP injection at a nonlethal dose causes a significant, but reversible thrombocytopenia. The carboplatin-induced thrombocytopenia is accompanied by an increase in circulating endogenous MGDF that precedes the return of circulating platelets to a normal level. MGDF mRNA is constitutively present in the liver. After carboplatin treatment, hepatic MGDF mRNA does not in-RA: Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl.
EGAKARYOCYTE GROWTH and development factor (MGDF) is a megakaryocyte growth and development factor identified in aplastic canine plasma.' Dog, mouse, and human MGDF cDNA clones have been isolated.' MGDF binds to c-mpl affinity columns and the biologic effects of MGDF are inhibited by soluble c-mpl.* The c-mpl ligand has been independently cloned by several groups of investigator^^'^ who have documented the in vitro and in vivo thrombopoietic effects of this novel protein.
Carboplatin, an analog of cisplatin, is a second generation platinum drug that is clinically effective in malignant tumors such as ovarian carcinoma, testicular carcinoma, and small cell carcinoma of the l~n g .~,~ Carboplatin's mechanism of action appears to be related to its ability to cross-link DNA.' Among carboplatin's toxicities are myelosuppression and thrombocytopenia. 6 The purpose of the present study is to report the ability of MGDF to significantly ameliorate carboplatin-induced thrombocytopenia.
M

MATERIALS AND METHODS
Human recombinant MGDF was expressed in Escherichia coli as a truncated form of the molecule.' Specific activity (1 X 10' U/mg) was measured with a factor-dependent murine cell line transfected with the human MGDF receptor (mpl) gene.' Cells were cultured with graded doses of MGDF for 72 hours and proliferation was measured with the Cell Titer 96 Aq assay kit according to manufacturer's instructions (Promega, Madison, WI). One unit is defined as the amount of material resulting in 50% maximal proliferation.
MGDF was injected intraperitoneally (IP) in a carrier solution of 1%
normal mouse serum dissolved in sterile saline. MGDF bioactivity in serum was measured by survival assays using interleukin-3 (IL-3) dependent murine 32D, clone 23 cells expressing murine mpl receptor. One thousand viable cells are incubated with serum samples diluted to 33% and 16.5% assay volume, and the remaining viable cells are counted microscopically after 3 days as previously described.* In the absence of MGDF, less than 100 viable cells remain after 3 days. In the presence of MGDF-containing serum, the cells survive and proliferate. The assay is semiquantitative and the results are plotted as an estimate of the viable cell number at the end of the 3-day assay. The maximum estimated number of cells in a confluent monolayer at the base of a well is approximately 6,400. MGDF bioactivity on days 0 to 17 was assayed on a total of 133 sera with a minimum of two sera and a maximum of 14 sera assayed on any given day. MGDF and GAPDH (glyceraldehyde-3-phosphatedehydrogenase) RNase protection assays on liver RNA were performed using the RPA I1 ribonuclease protection assay (Ambion, Austin, TX). Protected fragments were visualized on a PhosphorImager with ImageQuant software (Molecular Dynamics, Sunnyvale, CA). Soluble c-mpl levels in serum were measured by enzymelinked immunosorbent assay (ELISA) using microwells coated with affinity-purified anti-c-mpl antibodies. Samples or recombinant murine c-mpl as a standard were incubated for 18 to 24 hours at room temperature, and binding was detected with affinity-purified antic-mpl antibodies coupled to horseradish peroxidase. Balbk mice weighing approximately 20 gms and 8 weeks of age (Charles River Laboratories, Wilmington, MA) and with access to food and water ad libitum were used for all in vivo experiments. Carboplatin (Paraplatin, Bristol-Myers Squibb, Princeton, NJ) was reconstituted with sterile 0.9% NaCl and injected IP at a dose of 125 mgkg to induce thrombocytopenia. MGDF was injected daily IP beginning 1 day after the injection of carboplatin and with continued daily injections of MGDF for varying durations as described in the Results and figure legends. Peripheral blood was collected by tail bleeding 20 pL samples from mice held in a restrainer. White blood cell count, platelet count, and mean platelet volume (MPV) were measured with a Sysmex cell counter (Toa Medical, Kobe, Japan). Serum was collected by centrifugation of clotted whole blood obtained via cardiac puncture. Immunohistochemistry for the identification of megakaryocytes was performed with rabbit antihuman von Willebrand factor (Dako Corp, Carpenteria, CA) on 10% neutral buffered formalin-fixed, paraffin-embedded decalcified femurs sectioned longitudinally. The number of megakaryocytes in marrow and spleen per 10 randomly chosen 400 X magnification fields were counted 
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RESULTS
MGDF injected IP to Balb/c mice causes a dose-dependent thrombocytosis (Fig 1A) accompanied by a decrease in mean platelet volume (Fig 1B) . MGDF does not affect the circulating number of leukocytes (Fig 1C) . MGDF does not affect Days after Injection of Carboplatin   Fig 3. Carboplatin (125 mg/kg) causes a rapid decrease in circulating platelet number between days 5 t o 8 followed by a sustained thrombocytopenia and then rapid recovery of platelet numbers between days 15 t o 17. MPV gradually increases following the onset of thrombocytopenia and normalizes when the platelet count normalizes (n = 10 mice per group). Endogenous MGDF bioactivity is undetectable before the onset of thrombocytopenia and then increases rapidly as the platelet count drops. MGDF bioactivity is expressed in a semiquantitative cell-based bioassay as the number of cells per microwell' with a mean peak of approximately 1,000 t o 2,000 cellslwell on days 8 through 11 and with less than 100 cells/ well on days 0 t o 5.
precursors in the marrow and the release of platelets into the peripheral circulation (Fig 2) .
Carboplatin injected to Balb/c mice as a single IP injection at a dose of 125 mg/kg causes a significant, but reversible, thrombocytopenia (Fig 3) . Peripheral platelet num-B MGDF - bers stay at preinjection levels for the first S days after injection of carboplatin and then drop rapidly over days 6 to 8. The thrombocytopenia plateaus between days 8 to IS. Platelet numbers rapidly return to a control lcvcl ovcr the next 2 days. The carboplatin-induced thrombocytopenia is accompanied by an increase in circulating endogenous MGDF bioactivity that precedes the return of circulating platelets to a normal level (Fig 3) . The mean platelet volume increases during the period of thrombocytopenia and thcn rcturns towards normal as the platelet number normalizes. MGDF mRNA levels i n the liver do not increase in concordance with circulating MGDF levels ( Fig  4A) . MGDF mRNA expression in the livers of control and carboplatin-treated mice on day 8 were studied in a largcr number of mice to look more carefully for any increase in steady-state MGDF mRNA expression ( Fig 4B) . A very slight increase in the average ratio of MGDF/GAPDH mRNA expression in carboplatin-treated mice was noted by PhosphorImager analysis (MGDFGAPDH ratio is 0.9.5 -t 0. I2 in controls and I . 17 -t 0. I3 in carboplatin-treated mice, P < .OS), but the increase in hepatic steady-state MGDF mRNA does not parallel the magnitude of the increase in circulating MGDF bioactivity. Circulating soluble c-mpl receptor levels measured between days 0 and 14 (n = 26 mice killed before and during the course of carboplatin-induced thrombocytopenia) range between I .S reverses carboplatin-induced thrombocytopenia in a dosedependent fashion (Fig 5A) . In a second set of experiments in which the carboplatin-induced thrombocytopenia was not as severe, MGDF at 100 pg/kg completely prevented thrombocytopenia (Fig 5B) . In a third experiment, the normalization of circulating platelet numbers in carboplatin plus MGDF-treated mice on day 10 (Fig 6A) is shown to be accompanied by a normalization of megakaryocyte numbers in the bone marrow ( Fig 6B) and spleen ( Fig  6C) . The normalization of megakaryocyte numbers in the femur by MGDF treatment is histologically apparent after immunostaining for von Willebrand factor (Fig 7) . Carboplatin causes a slight transient decrease in hemoglobin that is not significantly ameliorated by MGDF (data not shown). For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 
DISCUSSION
An intensive scientific search to discover a humoral factor that will promote the growth and differentiation of megakaryocytes has culminated in the discovery of the c-mpl ligand MGDF.2-5.' MGDF may be useful in a variety of thrombocytopenic states in which inadequate platelet production plays a key role. Patients who have received chemotherapy for treatment of malignancy may develop severe thrombocytopenia that is potentially life-threatening because of the risk of hemorrhage. Thrombocytopenia limits the ability of oncologists to escalate chemotherapy doses and may, thereby, Limit the hope for remissions or cures in cancer patients. An agent to accelerate platelet recovery after chemotherapy in a fashion analagous to the way granulocyte colony-stimulating factor (G-CSF) promotes neutrophil recovery'" would be extremely useful. The present study demonstrates that MGDF fulfills the promise of ameliorating thrombocytopenia in a mouse model of carboplatin chemotherapy. Carboplatin, a commonly used agent in cancer chemotherapy, is a well-documented cause of thrombocytopenia in patients." In mice receiving carboplatin, the circulating level of endogenous MGDF was shown to increase at the time of rapidly decreasing platelet numbers, suggesting a role for endogenous MGDF in the regulation of circulating numbers of platelets. Interestingly and perhaps somewhat unexpectedly, MGDF mRNA expression in the liver (as related to expression of the housekeeping gene GAPDH) does not show an increase concordant with the increase noted in circulating MGDF, suggesting the possibility of either posttranscriptional regulation of MGDF gene expression or a role for circulating c-mpl levels in the regulation of MGDF bioactivity. Soluble circulating c-mpl levels, however, did not change appreciably at the time of increase in circulating MGDF bioactivity. The possibility also exists that platelet membrane c-mpl acts as a sink for free MGDF in a fashion similar to the possible role of neutrophil membrane G-CSF receptors in the regulation of free circulating G-CSF levels.I2
The in vivo effects on platelet numbers of several growth factors other than MGDF have been previously studied. IL-6, for example, has been reported to elevate the platelet count in carboplatin-pretreated rats." L-6 is also reported to accelerate recovery from hematopoietic depression in mice by stimulating multilineage hematop~iesis.'~ On the other hand, IL-6 apparently does not mediate the thrombopoietic response to acute thromb~cytopenia'~ and is not as specific a growth factor for platelets as is MGDF. L-3 is another growth factor that is hematologically more pleiotropic than MGDF, but that may nevertheless exert beneficial
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From effects on platelet numbers in patients."j The combination of IL-3 and IL-6 modestly enhanced platelet recovery after 5-fluorouracil induced thrombocytopenia in mice." IL-1, IL-7, and IL-1 1 have all also shown potentially promising effects on platelets, although definitive clinical trials remain to be cond~cted.""~"~ Clinical trials with MGDF will be necessary to determine the potential usefulness of MGDF, not only after chemotherapy, but also after bone marrow transplantation, as well as in other thrombocytopenic conditions.
